SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is trending as the community rallies around its position as a Bitcoin-native meme coin within the burgeoning Rune ecosystem. Discussions highlight the strong community, fair distribution, and the potential for $DOG to bridge Bitcoin culture with broader markets through its association with $CBLO. The community emphasizes holding through market volatility.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as traders discuss its potential as a privacy-focused alternative to Bitcoin, drawing comparisons to early BTC gains. Community members are pointing to recent investments from figures like the Winklevoss twins, as well as speculation around institutional adoption and regulatory environments favoring privacy coins. Some traders believe ZEC is inversely correlated to Bitcoin and are closely watching technical patterns for potential breakouts.

Memecoin on Injective taken over by the community.

Nonja

$NONJA is gaining traction as a meme coin on the Injective ($INJ) network, with community members highlighting its strong performance relative to $INJ and its robust, active community.  Discussion revolves around its potential for high returns, especially with the upcoming Injective EVM mainnet and potential ETFs, and the unique qualities of its NFT collections.  The community emphasizes $NONJA's strong fundamentals, burned liquidity, and status as a leading meme coin on the $INJ ecosystem.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPEV is trending amid discussions about its strategic shift towards AI and robotics, with the unveiling of the 'Iron' humanoid robot driving significant investor interest. The community is actively discussing the potential for XPEV to become a leader in physical AI, expanding beyond its current EV focus, with some comparing it favorably to Tesla. Bullish sentiment is also supported by strong delivery numbers and expansion into new global markets.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions surrounding the release of Epstein files and their potential implications for Trump. The community is focused on speculation about Trump's connections and any efforts to suppress the release. Political divides are fueling the conversation, with some questioning motives and potential impacts.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

JMIA is trending amid discussions about its recent earnings, investor day, and potential for a short squeeze. Community members are focused on the company's growth prospects in Africa and its path to profitability, with some expressing optimism about long-term targets and potential institutional investment. Bullish sentiment is fueled by perceived undervaluation and the stock's uncorrelated nature to other markets.

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

Cidara Therapeutics is trending due to positive sentiment around a potential acquisition by Merck for $9.2B, which sent the stock soaring. The community is discussing the impact of the deal on options, what happens to shares post-acquisition, and whether a bidding war might further increase the acquisition price. Some investors are also looking at similar companies that may be acquisition targets.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as the community discusses Warren Buffett's firm taking a new multi-billion dollar stake in Google's parent company, Alphabet, signaling a bet on AI and growth stocks. This move has sparked debate, with some seeing it as a smart shift away from Apple, while others question the timing and Buffett's value investing principles. The investment comes amidst market context showing a bullish trend for Berkshire, although the stock is nearing overbought territory.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is trending due to market uncertainty fueled by renewed US-China trade tensions and a broader tech sell-off; the immediate catalyst seems to be Trump's tariff threats, sparking fears of a deeper trade war. The community is actively discussing potential support levels, dip-buying opportunities, and whether this is a temporary pullback or the start of a larger correction, with some drawing comparisons to previous market crashes. There are mixed sentiments with some investors remaining bullish on the long-term prospects of tech and AI while others express concerns about inflated valuations and the potential impact of a prolonged government shutdown.

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

TENX is trending as investors discuss its strong cash position, low share float, and Phase 3 trials targeting a significant patient population. The community is highlighting the potential for a squeeze, drawing comparisons to other stocks with similar ownership structures and catalysts. Some are noting potential institutional interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's What Key Metrics Tell Us About Glaukos (GKOS) Q3 Earnings

Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

GKOS Stock Surges Following Q3 Earnings & Revenue Beat, Guidance Raised

Glaukos reported a narrower Q3 loss, strong 38% sales jump, and raised 2025 outlook as iDose TR and Epioxa fuel momentum across key franchises.

<ul class="summary-bullets"><li>Glaukos shares surged 21% in after-hours trading after the company posted record third-quarter revenue and raised its full-year guidance.</li><li>Strong glaucoma product sales, particularly in the U.S., drove a 38% year-over-year rise in total revenue, while losses narrowed and margins improved.</li><li>Retail sentiment on Stocktwits turned bullish, with users calling Glaukos a “hidden gem” and noting the stock’s chart “looks good.”</li></ul>Glaukos Corp shares climbed 21% in after-hours trading on Wednesday after the eye-care company delivered a strong third quarter (Q3) and raised its revenue expectations for the year.<h2 class="st-heading-2">Record Quarter</h2>The company reported $133.5 million in revenue, up 38% from a year earlier, helped by booming demand for its glaucoma products. U.S. glaucoma sales surged 57% to $80.8 million, lifting total glaucoma revenue to a record $110.2 million.Profitability also improved. Glaukos posted a gross margin of 78% and a non-GAAP margin of 84%, while trimming its net loss to $16.2 million, or $0.28 per share, from $21.4 million, or $0.39 per share, a year ago.<h2 class="st-heading-2">Outlook</h2>The company lifted its 2025 revenue forecast to $490 million-$495 million, up from a previous range of $480 million-$486 million. It also offered an early look at 2026 guidance, projecting sales between $600 million and $620 million.Glaukos closed the quarter with $277.5 million in cash and investments and no debt, underscoring a strong financial footing as it continues to expand its ophthalmic portfolio.<h2 class="st-heading-2">Stocktwits Users Call Glaukos A ‘Hidden Gem’&nbsp;</h2>On Stocktwits, retail sentiment for Glaukos was ‘bullish’ amid ‘high’ message volume.One user called Glaukos a “hidden gem,” saying they hoped the stock would finally get the attention it deserves.&nbsp;<stembedurl>https://stocktwits.com/erkdg/message/634255035</stembedurl>Another noted that the company’s chart was “looking good,” reflecting optimism about the stock’s technical setup.<stembedurl>https://stocktwits.com/TaoistTrader/message/634169905</stembedurl><a href="https://stocktwits.com/symbol/GKOS">Glaukos’ stock</a> has declined 49% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Glaukos Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Glaukos Stock Jumped Over 20% After-Hours Today

Glaukos shares surged 21% in after-hours trading after the company posted record third-quarter revenue and raised its full-year guidance.

Equity

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

Glaukos (GKOS) delivered earnings and revenue surprises of +40.74% and +9.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Glaukos Announces Third Quarter 2025 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today...

IQVIA Holdings (IQV) Tops Q3 Earnings and Revenue Estimates

IQVIA (IQV) delivered earnings and revenue surprises of +1.35% and +0.86%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Glaukos (GKOS) Report Negative Earnings Next Week? What You Should Know

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases...

Glaukos Builds Dual Growth Engines Amid Market Headwinds

GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Glaukos Corporation

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$90.03
Prev Close	$91.81
Open	$90.65
Dividend Yield	0.00%
50-Day Moving Average	$84.10
Beta	1.24
Avg. Volume	1.42M
PE Ratio	-58.05

52-Week High	$163.71
52-Week Low	$73.16
Market Capitalization	$5.28B
EPS (Annual)	-$2.77
Price to Book	6.71
Revenue Per Employee	$385,408.04
Enterprise Value/EBITDA	N/A

GKOS
Glaukos Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GKOS News

GKOSGlaukos Corporation